Basel areas hold promise for investors
Substantial efforts are underway in Basel to develop new areas and create space for people and companies. The efforts were welcomed by investors at the 17th Basler Investorengespräch.
The project Nordspitze exists for the area Dreispitz Nord (visualization: Herzog & de Meuron)
The 17th Basler Investorengespräch was held at the Kunstmuseum in Basel, according to the canton of Basel-Stadt. Executive Council President Elisabeth Ackermann welcomed 140 invited guests from across Switzerland who had sought to find out about the development of areas in Basel.
Occupying a total of 113 hectares, the areas under transformation are in central locations. In the coming 10 to 20 years, they will be developed with new living and working quarters in Basel’s effort to prepare for growth. The projects will create space for 20,000 new inhabitants and 30,000 jobs by 2035, confirmed Member of the Government of Basel-Stadt Hans-Peter Wessels in his speech.
Member of the Government Eva Herzog spoke about the research and administration site Areal Rosental Mitte, which is currently being transformed into a public quarter. There are plans to connect work with research and living space here, granting development opportunities to both companies in Basel and companies moving to the region. Lukas Ott, who heads cantonal and urban development in Basel-Stadt, also spoke about the variety of development across the areas. He said, Basel would do well to “develop its valuable transformation spaces gradually, flexibly and in a variety of ways”.
The event was rounded off by a panel about development in a rapidly changing market. Participants included cantonal architect Beat Aeberhard; the director of Immobilien Basel-Stadt, Rolf Borner; the head of development at SBB Immobilien, Susanne Zenker; and the CEO of Central Real Estate Basel AG, Andreas Fürst.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More